NLS Pharmaceutics ^{Priced, Nasdaq: NLSP}

We are an innovative biopharmaceutical company engaged in the discovery and development of life-improving drug therapies to treat rare and complex central nervous system, or CNS, disorders. CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance use disorders. According to the World Health Organization and based on data from the Global Burden of Disease Report, 25% of the world’s population suffers from at least one CNS disorder, resulting in a socio-economic burden of more than $317 billion annually in the United States alone. Additionally, CNS disorders are expected to account for approximately 15% of the global disease burden by 2020, the largest burden of any disease area. However, treatment options for these conditions are often limited, inadequate or nonexistent, and the development of new CNS treatments generally trails behind other therapeutic areas. We are pursuing the development of the next generation of CNS therapies with high medical impact to address this critical and growing unmet need.